Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-25-117825
Filing Date
2025-05-12
Accepted
2025-05-12 16:32:36
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A d895609ddefa14a.htm DEFA14A 11049
2 GRAPHIC g895609g04a01.jpg GRAPHIC 166088
3 GRAPHIC g895609g05a01.jpg GRAPHIC 196799
  Complete submission text file 0001193125-25-117825.txt   511335
Mailing Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758
Business Address 12407 N. MOPAC EXPY. SUITE 250 #390 AUSTIN TX 78758 7378021989
Rein Therapeutics, Inc. (Filer) CIK: 0001420565 (see all company filings)

EIN.: 134196017 | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-38130 | Film No.: 25935398
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)